141 related articles for article (PubMed ID: 30499053)
21. Targeting CTCFL/BORIS for the immunotherapy of cancer.
Loukinov D
Cancer Immunol Immunother; 2018 Dec; 67(12):1955-1965. PubMed ID: 30390146
[TBL] [Abstract][Full Text] [Related]
22. MAGEA1 inhibits the expression of BORIS via increased promoter methylation.
Zhao J; Wang Y; Liang Q; Xu Y; Sang J
J Cell Sci; 2019 Jan; 132(1):. PubMed ID: 30498011
[TBL] [Abstract][Full Text] [Related]
23. Down-regulation of BORIS/CTCFL efficiently regulates cancer stemness and metastasis in MYCN amplified neuroblastoma cell line by modulating Wnt/β-catenin signaling pathway.
Garikapati KR; Patel N; Makani VKK; Cilamkoti P; Bhadra U; Bhadra MP
Biochem Biophys Res Commun; 2017 Feb; 484(1):93-99. PubMed ID: 28104398
[TBL] [Abstract][Full Text] [Related]
24. A Common Polymorphism within the IGF2 Imprinting Control Region Is Associated with Parent of Origin Specific Effects in Infantile Hemangiomas.
Schultz B; Yao X; Deng Y; Waner M; Spock C; Tom L; Persing J; Narayan D
PLoS One; 2015; 10(10):e0113168. PubMed ID: 26496499
[TBL] [Abstract][Full Text] [Related]
25. Expression of the epigenetic factor BORIS (CTCFL) in the human genome.
de Necochea-Campion R; Ghochikyan A; Josephs SF; Zacharias S; Woods E; Karimi-Busheri F; Alexandrescu DT; Chen CS; Agadjanyan MG; Carrier E
J Transl Med; 2011 Dec; 9():213. PubMed ID: 22168535
[TBL] [Abstract][Full Text] [Related]
26. Rare exonic minisatellite alleles in MUC2 influence susceptibility to gastric carcinoma.
Jeong YH; Kim MC; Ahn EK; Seol SY; Do EJ; Choi HJ; Chu IS; Kim WJ; Kim WJ; Sunwoo Y; Leem SH
PLoS One; 2007 Nov; 2(11):e1163. PubMed ID: 18000536
[TBL] [Abstract][Full Text] [Related]
27. Expression analysis of BORIS during pluripotent, differentiated, cancerous, and non-cancerous cell states.
Soltanian S; Dehghani H; Matin MM; Bahrami AR
Acta Biochim Biophys Sin (Shanghai); 2014 Aug; 46(8):647-58. PubMed ID: 24928684
[TBL] [Abstract][Full Text] [Related]
28. BORIS and CTCF are overexpressed in squamous intraepithelial lesions and cervical cancer.
Velázquez-Hernández N; Reyes-Romero MA; Barragán-Hernández M; Guerrero-Romero F; Rodríguez-Moran M; Aguilar-Durán M; Lazalde Medina B
Genet Mol Res; 2015 Jun; 14(2):6094-100. PubMed ID: 26125810
[TBL] [Abstract][Full Text] [Related]
29. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer.
Gu J; Zhao H; Dinney CP; Zhu Y; Leibovici D; Bermejo CE; Grossman HB; Wu X
Clin Cancer Res; 2005 Feb; 11(4):1408-15. PubMed ID: 15746040
[TBL] [Abstract][Full Text] [Related]
30. Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions.
Pugacheva EM; Rivero-Hinojosa S; Espinoza CA; Méndez-Catalá CF; Kang S; Suzuki T; Kosaka-Suzuki N; Robinson S; Nagarajan V; Ye Z; Boukaba A; Rasko JE; Strunnikov AV; Loukinov D; Ren B; Lobanenkov VV
Genome Biol; 2015 Aug; 16(1):161. PubMed ID: 26268681
[TBL] [Abstract][Full Text] [Related]
31. Rare minisatellite alleles of MUC2-MS8 influence susceptibility to rectal carcinoma.
Seol SY; Yang GE; Cho Y; Kim MC; Choi HJ; Choi YH; Leem SH
Genes Genomics; 2021 Dec; 43(12):1381-1388. PubMed ID: 34436741
[TBL] [Abstract][Full Text] [Related]
32. Association of the PIG3 promoter polymorphism with invasive bladder cancer in a Japanese population.
Ito M; Nishiyama H; Watanabe J; Kawanishi H; Takahashi T; Kamoto T; Habuchi T; Ogawa O
Jpn J Clin Oncol; 2006 Feb; 36(2):116-20. PubMed ID: 16418181
[TBL] [Abstract][Full Text] [Related]
33. BORIS/CTCFL expression activates the TGFβ signaling cascade and induces Drp1 mediated mitochondrial fission in neuroblastoma.
Makani VKK; Mendonza JJ; Edathara PM; Yerramsetty S; Pal Bhadra M
Free Radic Biol Med; 2021 Nov; 176():62-72. PubMed ID: 34534628
[TBL] [Abstract][Full Text] [Related]
34. Discovering a binary CTCF code with a little help from BORIS.
Lobanenkov VV; Zentner GE
Nucleus; 2018 Jan; 9(1):33-41. PubMed ID: 29077515
[TBL] [Abstract][Full Text] [Related]
35. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis.
Li C; Wu W; Liu J; Qian L; Li A; Yang K; Wei Q; Zhou J; Zhang Z
Pharmacogenet Genomics; 2006 Apr; 16(4):245-51. PubMed ID: 16538171
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies.
Hoffmann MJ; Müller M; Engers R; Schulz WA
Biochem Pharmacol; 2006 Nov; 72(11):1577-88. PubMed ID: 16854382
[TBL] [Abstract][Full Text] [Related]
37. Do DNA repair genes OGG1, XRCC3 and XRCC7 have an impact on susceptibility to bladder cancer in the North Indian population?
Gangwar R; Ahirwar D; Mandhani A; Mittal RD
Mutat Res; 2009; 680(1-2):56-63. PubMed ID: 19815090
[TBL] [Abstract][Full Text] [Related]
38. Polymorphisms in XPD exons 10 and 23 and bladder cancer risk.
Schabath MB; Delclos GL; Grossman HB; Wang Y; Lerner SP; Chamberlain RM; Spitz MR; Wu X
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):878-84. PubMed ID: 15824159
[TBL] [Abstract][Full Text] [Related]
39. The hTERT-VNTR2-2
Kwon JA; Jeong MS; Yoon SL; Mun JY; Kim MH; Yang GE; Park SH; Chung JW; Choi YH; Cha HJ; Leem SH
Genes Genomics; 2019 Dec; 41(12):1517-1525. PubMed ID: 31691174
[TBL] [Abstract][Full Text] [Related]
40. Increased expression of brother of the regulator of imprinted sites in peripheral blood neutrophils is associated with both benign and malignant breast lesions.
El-Sharkawy NM; Radwan WM; Essa ES; Kandeel EZ; Abd El-Fattah EK; Kandil SH; Kamel AM
Cytometry B Clin Cytom; 2017 Sep; 92(5):355-360. PubMed ID: 27219508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
